Dr. Shuhong Zhang serves as Vice President of Development Sciences at AbbVie. She is responsible for preclinical safety, ADME characterization, CMC development and clinical drug supplies to enable the discovery and development of innovative therapies that help improve the lives of patients around the world.
Dr. Zhang joined AbbVie 2005 as Project Leader and Head of Analytical Chemistry in Process R&D. In 2012, she was named Vice President of Process R&D and in 2018 Vice President for all of Development Sciences. In this role, she has been instrumental in building the CMC strategies that have contributed to successful approval of recent AbbVie products in oncology, hepatitis C and endometriosis. Dr. Zhang has also been active at the interface of discovery and development to accelerate AbbVie’s programs into human trials.
Prior to AbbVie, Dr. Zhang held roles at Pfizer in both its small molecule and biologics R&D teams. She completed her undergraduate study in chemistry at Beijing University and received a Ph.D. in chemical engineering from Yale University